文献速递慢性肾脏病血液净化与透析

从证据到行动:推进2型糖尿病合并CKD患者及时启动三联治疗

From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 Diabetes Mellitus and CKD.
PubMed 文献 · Kidney Int Rep · 2025-10-01

本文指出2型糖尿病合并慢性肾脏病(CKD)治疗中指南落地是主要瓶颈,包括缺乏白蛋白尿检测和延迟启动RASi、SGLT2i与nsMRA三联治疗。强调RASi-SGLT2i残余风险及nsMRA附加价值,并基于流行病学数据提出>90%合格患者可在初级保健中诊治。CONFIDENCE试验支持在RASi背景下同时处方nsMRA与SGLT2i的安全性和减少白蛋白尿的疗效。

要点

  • 2型糖尿病合并CKD应广泛开展白蛋白尿检测以早期发现CKD。
  • RASi-SGLT2i基础上加用nsMRA可进一步降低残余风险。
  • >90%合格患者可在初级保健中诊治,需多学科协作。

核心结论

  • 在初级保健中广泛开展白蛋白尿评估,可避免2型糖尿病合并CKD患者漏诊或延迟启动指南导向治疗。
  • RASi-SGLT2i治疗存在残余风险,加用nsMRA可带来额外肾脏和心血管获益。

研究设计与样本

  • 本文为综述/评论性文章,基于流行病学数据和CONFIDENCE试验等证据进行论述。

主要发现

  • 加用nsMRA可能将肾脏替代治疗(KRT)的需求延迟长达十年。
  • 基于流行病学数据,>90%的合格患者可在初级保健机构中被诊断和管理。
  • CONFIDENCE试验支持在既往RASi背景下同时处方nsMRA与SGLT2i联合治疗的安全性和减少白蛋白尿的疗效。

关键数值与推荐

  • 三联治疗包括RASi、SGLT2i和nsMRA。
  • CONFIDENCE试验评估nsMRA联合SGLT2i在RASi背景上的安全性和白蛋白尿降低疗效。

临床怎么用

  • 初级保健应广泛开展白蛋白尿检测以早期识别CKD。
  • 在无禁忌时最大化使用RASi和SGLT2i,并快速启动三联治疗。
  • 初级保健应与肾内科、内分泌科、心内科和内科紧密协作管理患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Amid rapid advances in treating chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM) and evolving guidelines, implementation remains a major bottleneck. Suboptimal implementation of guidelines, from lack of albuminuria testing for early CKD detection to delayed initiation of triple therapy with renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and nonsteroidal mineralocorticoid receptor antagonists (nsMRA), may deny patients kidney and cardiovascular benefits. We emphasize the residual risk despite RASi-SGLT2i therapy and the added value of nsMRA, and address real-world implementation challenges. The addition of a nsMRA may delay the need for kidney replacement therapy (KRT) by up to a decade. Based on epidemiological data, > 90% of patients eligible for therapy may be diagnosed and managed in the primary care setting, identifying the owners of the process, in close collaboration with nephrology, endocrinology, cardiology, and internal medicine, as needed. In addition, primary care provides the optimal setting, given the easy and repeated contact, for ensuring lifestyle measures essential to nephroprotection, as well as maximizing the use of RASi and SGLT2 inhibitors when not contraindicated, together with the rapid initiation of triple therapy, facilitated by its safety profile. In this regard, the CONFIDENCE trial supports the safety and efficacy (in terms of albuminuria reduction) of prescribing simultaneously, nsMRA plus SGLT2i combination therapy on a prior RASi background. In conclusion, widespread uptake of albuminuria assessment in primary care will prevent patients with CKD and T2DM from missing out on the diagnosis or the rapid implementation of optimal guideline-directed therapy.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Fernandez-Fernandez B, Gorriz JL, Cebrian-Cuenca A, et al. From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 Diabetes Mellitus and CKD. Kidney Int Rep. 2025. PMID: 41541781. doi:10.1016/j.ekir.2025.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。